New hope for advanced ovarian cancer: experimental combo aims to shrink tumors before surgery
NCT ID NCT07407452
Summary
This study is testing whether adding two new immunotherapy drugs to standard chemotherapy (or to a different chemotherapy plus another targeted drug) can better shrink advanced ovarian tumors before surgery. The goal is to see if this approach helps more patients become eligible for tumor-removing surgery and improves their outcomes. The trial will enroll 50 women with advanced ovarian cancer who haven't had previous cancer treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.